An Updated Overview of Cyclodextrin-Based Drug Delivery Systems for Cancer Therapy
Cyclodextrins (CDs) attracted increasing interest over the past few years, leading to the emergence of promising anti-tumor nanomedicines. Tackling their
Tag: HPBCD
Nature.com: HPBCD treatment improves learning and executive function in Alzheimer model mice
Earlier we have reported on a patent appication related to HPBCD treatment in Alzheimer’s disease based on the invention of
HPBCD-enabled metal nanoclusters for selective labeling of lysosomes
The controllable self-assembly of metal nanoclusters (NCs) has attracted great interest because of the morphological versatility and accompanying luminescence properties,
First Patient Enrolled in Phase 1 Study of Midatech’s Panobinostat / HPBCD (MTX-110) for Recurrent Glioblastoma
Midatech Pharma PLC, an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, announced on 14 November
Oral Xe-Cyclodextrin for cardiovascular protection
Cardiac hypertrophy often causes impairment of cardiac function. Xenon (Xe), a naturally occurring noble gas, is known to provide neurological
Australian company pioneering Cavadextrin for regression of atherosclerosis
Newsmaker, the Australian Press Release Distribution Service has published the news on “An Australian pioneering a medical breakthrough treatment that
Inclusion Solves Insolubility ―Translational Research Cycle from Bedside to Bench and Bench to Bedside for Drug Development Targeting Niemann-Pick Disease Type C
Cyclodextrins (CDs) are used not only as pharmaceutical excipients but also as active pharmaceutical ingredients. CDs can act as artificial
Monosubstituted Maltosyl Cyclodextrins for the Potential Treatment of NPC
Niemann-Pick type C is a sever lysosomal storage disease, commonly refereed as ‘children’s Alzheimer’. There is no cure for it
MIT scientists filed patent for HPBCD treatment in Alzheimer’s disease
Li-Huei Tsai, director of Picower Institute for Learning and Memory (Massachusetts Institute of Technology) and her coworkers recently filed a patent
Inaugural Lecture of Prof. Szente at the Hungarian Academy of Sciences
Lajos Szente, Ph.D., D.Sc., one of the founders and former CEO (now Scientific Advisor) of CycloLab at the company and